Quick exit for Medicxi as Incyte buys vitiligo company Villaris

Medicxi’s 2019 seed investment in UMass spinout Villaris has resulted in a quick exit for the firm via Incyte’s acquisition of the company and its sole asset, a mAb to treat vitiligo.

Incyte Corp. (NASDAQ:INCY) will pay $70 million up front to acquire Villaris Therapeutics Inc. in a heavily back-loaded deal that includes $310 million in developmental and regulatory milestones, plus nearly $1.1 billion in commercial milestones...